Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010 (2010), Article ID 760402, 5 pages
http://dx.doi.org/10.1155/2010/760402
Case Report

Temozolomide-Induced Myelodysplasia

1Department of Internal Medicine, The Methodist Hospital, Smith Tower 1001, 6550 Fannin Street, Houston, TX 77030, USA
2School of Public Health, University of Colorado, Summit Toxicology, L.L.P., 1944 Cedaridge Circle, Superior, CO 80027, USA

Received 23 July 2009; Revised 17 November 2009; Accepted 13 January 2010

Academic Editor: Maria R. Baer

Copyright © 2010 Ethan A. Natelson and David Pyatt. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Lichtman, “Battling the hematological malignancies: the 200 years' war,” Oncologist, vol. 13, no. 2, pp. 126–138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. E. A. Natelson, “Benzene-induced acute myeloid leukemia: a clinician's perspective,” American Journal of Hematology, vol. 82, no. 9, pp. 826–830, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Deschler and M. Lübbert, “Acute myeloid leukemia: epidemiology and etiology,” Cancer, vol. 107, no. 9, pp. 2099–2107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Leone, L. Mele, A. Pulsoni, F. Equitani, and L. Pagano, “The incidence of secondary leukemias,” Haematologica, vol. 84, no. 10, pp. 937–945, 1999. View at Google Scholar · View at Scopus
  5. R. A. Larson and M. M. Le Beau, “Therapy-related myeloid leukaemia: a model for leukemogenesis in humans,” Chemico-Biological Interactions, vol. 153-154, pp. 187–195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Praga, J. Bergh, J. Bliss et al., “Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4179–4191, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Kollmannsberger, J. Beyer, J.-P. Droz et al., “Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3386–3391, 1998. View at Google Scholar · View at Scopus
  8. J. A. Knight, A. D. Skol, A. Shinde et al., “Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility,” Blood, vol. 113, no. 22, pp. 5575–5582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Bolufer, M. Collado, E. Barragán et al., “Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia,” British Journal of Haematology, vol. 136, no. 4, pp. 590–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Rund, S. Krichevsky, S. Bar-Cohen et al., “Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients,” Leukemia, vol. 19, no. 11, pp. 1919–1928, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Borthakur, E. Lin, N. Jain et al., “Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia,” Cancer, vol. 115, no. 14, pp. 3217–3221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. N. Singh, D. Huo, J. Anastasi et al., “Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant,” American Journal of Clinical Pathology, vol. 127, no. 2, pp. 197–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Orazi, “Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases,” Pathobiology, vol. 74, no. 2, pp. 97–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. D. Irons, L. Lv, S. A. Gross et al., “Chronic exposure to benzene results in a unique form of dysplasia,” Leukemia Research, vol. 29, no. 12, pp. 1371–1380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. R. D. Irons, S. A. Gross, X. Q. Wang et al., “Integrating WHO 2001–2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): A case-case analysis of benzene exposure,” Chemico-Biological Interactions. In press. View at Publisher · View at Google Scholar
  16. M. A. Ruiz, L. G. S. Augusto, J. Vassallo, A. C. Vigorito, I. Lorand-Metze, and C. A. Souza, “Bone marrow morphology in patients with neutropenia due to chronic exposure to organic solvents (benzene): early lesions,” Pathology Research and Practice, vol. 190, no. 2, pp. 151–154, 1994. View at Google Scholar · View at Scopus
  17. M. S. Linet, S.-N. Yin, L. B. Travis et al., “Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China,” Environmental Health Perspectives, vol. 104, supplement 6, pp. 1353–1364, 1996. View at Google Scholar · View at Scopus
  18. R. A. Kyle, R. V. Pierre, and E. D. Bayrd, “Multiple myeloma and acute myelomonocytic leukemia,” The New England Journal of Medicine, vol. 283, no. 21, pp. 1121–1125, 1970. View at Google Scholar · View at Scopus
  19. F. E. Van Leeuwen, “Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment,” Baillière's Clinical Haematology, vol. 9, no. 1, pp. 57–85, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Ellis and M. Boggild, “Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?” Multiple Sclerosis, vol. 15, no. 4, pp. 505–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. C. Chamberlain and J. Raizer, “Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia,” Journal of Neuro-Oncology, vol. 93, no. 2, pp. 229–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Khasraw, D. Bell, and H. Wheeler, “Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?” Journal of Clinical Neuroscience, vol. 16, no. 6, pp. 854–855, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 997–1003, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Dunn, A. Baborie, F. Alam et al., “Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy,” British Journal of Cancer, vol. 101, no. 1, pp. 124–131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Cunningham, M. M. Patnaik, D. E. Hammerschmidt, and G. M. Vercellotti, “Historical perspective and clinical implications of the Pelger-Huet cell,” American Journal of Hematology, vol. 84, no. 2, pp. 116–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. H. Greene, R. C. Young, J. M. Merrill, and V. T. DeVita, “Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma,” Cancer Research, vol. 43, no. 4, pp. 1891–1898, 1983. View at Google Scholar · View at Scopus
  27. G. V. Koukourakis, V. Kouloulias, G. Zacharias et al., “Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy,” Molecules, vol. 14, no. 4, pp. 1561–1577, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Chakravarti, M. G. Erkkinen, U. Nestler et al., “Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms,” Clinical Cancer Research, vol. 12, no. 15, pp. 4738–4746, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. R. J. Hansen, R. Nagasubramanian, S. M. Delaney, L. D. Samson, and M. E. Dolan, “Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice,” Carcinogenesis, vol. 28, no. 5, pp. 1111–1116, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Kaina, M. Christmann, S. Naumann, and W. P. Roos, “MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents,” DNA Repair, vol. 6, no. 8, pp. 1079–1099, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. A. D. Adema, K. van der Born, R. J. Honeywell, and G. J. Peters, “Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines,” Journal of Chemotherapy, vol. 21, no. 3, pp. 338–346, 2009. View at Google Scholar · View at Scopus
  32. Y. Hirose and H. Sano, “Molecular pharmacology on DNA methylating agent temozolomide,” Neurological Surgery, vol. 35, no. 2, pp. 117–129, 2007. View at Google Scholar · View at Scopus
  33. G. Viola, L. Cecconet, A. Leszl et al., “Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 6, pp. 1235–1251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Singhal, S. Selva-Nayagam, and M. P. Brown, “Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment—case study and review of literature,” Journal of Neuro-Oncology, vol. 85, no. 2, pp. 229–230, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. J. L. Villano, C. A. Collins, E. E. Manasanch, C. Ramaprasad, and K. van Besien, “Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide,” Lancet Oncology, vol. 7, no. 5, pp. 436–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. B. J. George, J. B. Eichinger, T. J. Richard et al., “A rare case of aplastic anemia caused by temozolomide,” Southern Medical Journal, vol. 102, no. 9, pp. 974–976, 2009. View at Google Scholar · View at Scopus
  37. M. E. Figueroa, L. Skrabanek, Y. Li et al., “MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation,” Blood, vol. 114, no. 16, pp. 3448–3458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. W. J. Kil, D. Cerna, W. E. Burgan et al., “In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide,” Clinical Cancer Research, vol. 14, no. 3, pp. 931–938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. C. E. Fadul, L. S. Kingman, L. P. Meyer et al., “A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme,” Journal of Neuro-Oncology, vol. 90, no. 2, pp. 229–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Tentori and G. Graziani, “Recent approaches to improve the antitumor efficacy of temozolomide,” Current Medicinal Chemistry, vol. 16, no. 2, pp. 245–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. V. Noronha, N. Berliner, K. K. Ballen et al., “Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature,” Neuro-Oncology, vol. 8, no. 3, pp. 280–283, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. R. Perry, M. T. Brown, and J. P. Gockerman, “Acute leukemia following treatment of malignant glioma,” Journal of Neuro-Oncology, vol. 40, no. 1, pp. 39–46, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. Y.-W. Su, M.-C. Chang, M.-F. Chiang, and R.-K. Hsieh, “Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma,” Journal of Neuro-Oncology, vol. 71, no. 3, pp. 315–318, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Whysner, M. V. Reddy, P. M. Ross, M. Mohan, and E. A. Lax, “Genotoxicity of benzene and its metabolites,” Mutation Research, vol. 566, no. 2, pp. 99–130, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. G. J. Morgan and C. L. Alvares, “Benzene and the hemopoietic stem cell,” Chemico-Biological Interactions, vol. 153-154, pp. 217–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. W. S. Stillman, M. Varella-Garcia, and R. D. Irons, “The benzene metabolite, hydroquinone, selectively induces 5q31− and −7 in human CD34+CD19 bone marrow cells,” Experimental Hematology, vol. 28, no. 2, pp. 169–176, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Wilbur, S. Keith, O. Faroon et al., Toxicological Profile for Benzene, U.S. Department of Health and Human Services, Atlanta, Ga, USA, 2007.
  48. R. D. Brunning, A. Orazi, U. Germing et al., “Myelodysplastic syndromes/neoplasms, overview,” in World Health Organization: Classification of Tumors of Haematopoietic and Lymphoid Tissues, S. H. Swerdlow et al., Ed., pp. 88–93, International Agency for Research on Cancer, Lyon, France, 4th edition, 2008. View at Google Scholar
  49. G. M. H. Swaen, T. Scheffers, J. De Cock, J. Slangen, and H. Drooge, “Leukemia risk in caprolactam workers exposed to benzene,” Annals of Epidemiology, vol. 15, no. 1, pp. 21–28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. A. S. Constantini, M. Quinn, D. Consonni, and M. Zappa, “Exposure to benzene and risk of leukemia among shoe factory workers,” Scandinavian Journal of Work, Environment and Health, vol. 29, no. 1, pp. 51–59, 2003. View at Google Scholar · View at Scopus
  51. P. R. Williams, J. M. Panko, K. Unice, J. L. Brown, and D. J. Paustenbach, “Occupational exposures associated with petroleum-derived products containing trace levels of benzene,” Journal of Occupational and Environmental Hygiene, vol. 5, no. 9, pp. 565–574, 2008. View at Publisher · View at Google Scholar · View at Scopus